FSFI endpoint is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-16. Numbers and descriptions here follow the published literature rather than marketing material.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized powder form |
| Solubility class | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or lower | Desiccated and protected from light |
| Typical analytical method | Reversed-phase HPLC with UV detection | Purity reported by area normalization |
| Common synonyms | PT-141; bremelanotide | Research code and assigned generic name |
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
=== Disorders of osteoid mineralization === Defective mineralization of osteoid leads to several important clinical conditions characterized by accumulation of unmineralized matrix. Rickets: Occurs in children when defective mineralization affects the growth plate and osteoid. The condition results from calcium or phosphate deficiency, either isolated or secondary to vitamin D deficiency. In rickets, the mineralization defect leads to accumulation of osteoid in bone tissue below the growth plate, resulting in weak bones and deformities. Osteomalacia: The adult equivalent of rickets, osteomalacia is characterized by softened bones due to impaired mineralization of osteoid. Vitamin D deficiency is the most common cause, though calcium or phosphate deficiency can also result in osteomalacia. The condition manifests as bone pain, muscle weakness, and increased fracture risk. Histomorphometric characteristics of osteomalacia include:
It is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase. Pyroglutamate is found in many proteins including bacteriorhodopsin. N-terminal glutamic acid and glutamine residues can spontaneously cyclize to become pyroglutamate, or enzymatically converted by glutaminyl cyclases. This is one of several forms of blocked N-termini which present a problem for N-terminal sequencing using Edman chemistry, which requires a free primary amino group not present in pyroglutamic acid. The enzyme pyroglutamate aminopeptidase can restore a free N-terminus by cleaving off the pyroglutamate residue. Pyroglutamic acid exists as two distinct enantiomers:
While Cannon Gladiator 4 is destroyed by Deka Base Robo, Gyanjava escapes from the Kaijuki, only for Yaako to disable his Muscle Gear before Deka Red S.W.A.T. Mode deletes him. Gyanjava is voiced by Yoshinori Okamoto, who also portrays his human form. Yuilwerian Mime (ユイルワー星人ミーメ, Yuiruwā Seijin Mīme): A spotty-eyed stag beetle–themed criminal from Planet Yuilwer who invades young women's dreams to steal their souls and create a youth potion from them. After targeting Umeko and attempting to use a Kaijuki called Megaroria 2 (メガロリア2, Megaroria Tsū) to further her plans, she is deleted by Deka Yellow and Pink in their S.W.A.T. Modes while Megaroria 2 is destroyed by Deka Wing Robo. Mime is voiced by Michie Tomizawa (富沢 美智恵, Tomizawa Michie). Guirarkian Don Bianco (ギラーク星人ドン・ビアンコ, Girāku Seijin Donbianko): A white tiger–themed member of the Intergalactic Mafia from Planet Guirark, and rival of Don Blaco, who is attacked and killed by Jingi. Don Bianco is voiced by Daisuke Egawa (江川 大輔, Egawa Daisuke). Zabunian Don Blaco (ザブン星人ドン・ブラコ, Zabun Seijin Donburako): A lion-themed member of the Intergalactic Mafia from Planet Zabun, and rival of Don Bianco, who hires Jingi to kill Bianco, only to be killed by the assassin as well. Don Blaco is voiced by Shigenori Sōya (宗矢 樹頼, Sōya Shigenori).
Their vows make everyone forget the "dire situation" for a moment, until Ari suddenly collapses. Ari succumbs to the cancer and his death aired on 7 March 2022. After the episode was broadcast aired, Kipa-Williams took to his Instagram account to post a thank you message to the show's cast, crew, and fans for their support. He said "This Iconic Ozzie TV show took risks. I'm honoured to have co-created Māori cultural storylines, and will forever be proud of those scenes that made it to screen.. it was true teamwork.. My hope is this opens the door for more diversity. Thank you for everything Ariki Wiremu Parata, you taught me a lot. I'm gonna miss you." The character made one final appearance on 15 March 2022, as Ari appears to Mia in a dream. The following year, Kipa-Williams revealed that he quit Home and Away because of "a calling" to the Māori culture. He moved back to Aotearoa, where he bought a farm and began lessons in te reo in order to become more fluent in the language.
==== Detoxification and drug metabolism ==== Enzymes such as CYP3A4, along with the antiporter activities, are also instrumental in the intestine's role of drug metabolism in the detoxification of antigens and xenobiotics.
Sources: en.wikipedia.org
== Ecology == Penicillium digitatum is found in the soil of areas cultivating citrus fruit, predominating in high temperature regions. In nature, it is often found alongside the fruits it infects, making species within the genus Citrus its main ecosystem. It is only within these species that P. digitatum can complete its life cycle as a necrotroph. However, P. digitatum has also been isolated from other food sources. These include hazelnuts, pistachio nuts, kola nuts, black olives, rice, maize, and meats. Low levels have also been noted in Southeast Asian peanuts, soybeans, and sorghum.
The Great Zimbabwe Bird first appeared in an armorial sense when it was incorporated in the coat of arms of Southern Rhodesia, which were granted by Royal Warrant on 11 August 1924. It was first used on a national flag when the full arms were displayed on the Rhodesian flag that was adopted on 11 November 1968. It then appeared alone on the Zimbabwe Rhodesian flag of 1979, and it is now displayed on the flag of Zimbabwe. The arms of 1924 were initially retained by the Zimbabwean Government until a new coat of arms were adopted on 12 September 1981. The Zimbabwe Bird depicted on the flag is rendered in the same format as it appeared on the arms of 1924 and as it appeared on the Rhodesian flag of 1968 and the Zimbabwe Rhodesian flag of 1979. The red star on which the bird is placed is a regular star. However, a different, rather flattened version of the bird, sometimes displayed on an irregular, flattened star, is often seen on flags that are manufactured outside of Zimbabwe. The origin of this discrepancy appears to be an illustration of the proposed new flag that was first released by the Zimbabwe Ministry of Information in April 1980, just prior to the country attaining full independence. This illustration showed the bird in a flattened version positioned over an irregular star.
== History == Experimentally the first examples of mechanically interlocked molecular architectures appeared in the 1960s with catenanes being synthesized by Wasserman and Schill and rotaxanes by Harrison and Harrison. The chemistry of MIMAs came of age when Sauvage pioneered their synthesis using templating methods. In the early 1990s the usefulness and even the existence of MIMAs were challenged. The latter concern was addressed by X ray crystallographer and structural chemist David Williams. Two postdoctoral researchers who took on the challenge of producing [5]catenane (olympiadane) pushed the boundaries of the complexity of MIMAs that could be synthesized their success was confirmed in 1996 by a solid‐state structure analysis conducted by David Williams.
There are two known receptors for the vasoactive intestinal peptide (VIP) termed VPAC1 and VPAC2. These receptors bind both VIP and pituitary adenylate cyclase-activating polypeptide (PACAP) to some degree. Both receptors are members of the 7 transmembrane G protein-coupled receptor family. VPAC1 is distributed widely in the CNS, liver, lung, intestine and T-lymphocytes. VPAC2 is found in the CNS, pancreas, skeletal muscle, heart, kidney, adipose tissue, testis, and stomach. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors are activated by the endogenous peptides VIP, PACAP-38, PACAP-27, peptide histidine isoleucineamide (PHI), peptide histidine methionineamide (PHM) and peptide histidine valine (PHV). “PACAP type II receptors” (VPAC1 and VPAC2 receptors) display comparable affinity for PACAP and VIP, whereas PACAP-27 and PACAP-38 are >100 fold more potent than VIP as agonists of most isoforms of the PAC1 receptor.
=== Body image === Many women regard their breasts as important to their sexual attractiveness, as a sign of femininity that is important to their sense of self. A woman with smaller breasts may regard her breasts as less attractive.
Sources: en.wikipedia.org
== History == Creatine was first identified in 1832 when Michel Eugène Chevreul isolated the precipitate from the basified water-extract of skeletal muscle. He later named the crystallized precipitate after the Greek word for meat, κρέας (kreas). In 1928, creatine was shown to exist in equilibrium with creatinine. Studies in the 1920s showed that consumption of large amounts of creatine did not result in its excretion. This result pointed to the ability of the body to store creatine, which in turn suggested its use as a dietary supplement. In 1912, Harvard University researchers Otto Folin and Willey Glover Denis found evidence that ingesting creatine can dramatically boost the creatine content of the muscle. The discovery of phosphocreatine was reported in 1927. In the 1960s, the enzyme creatine kinase was shown to phosphorylate ADP using phosphocreatine to generate ATP and thus buffering the ATP/ADP ratio. While creatine's influence on physical performance has been well documented since the early twentieth century, it came into public view following the 1992 Olympics in Barcelona. An 7 August 1992 article in The Times reported that Linford Christie, the gold medal winner at 100 metres, had used creatine before the Olympics. An article in Bodybuilding Monthly named Sally Gunnell, who was the gold medalist in the 400-metre hurdles, as another creatine user. In addition, The Times also noted that 110 metre hurdler Colin Jackson began taking creatine before the Olympics.
In late 1915 the British High Commissioner to Egypt, Henry McMahon, exchanged ten letters with Hussein bin Ali, Sharif of Mecca, in which he promised Hussein to recognize Arab independence "in the limits and boundaries proposed by the Sherif of Mecca" in return for Hussein launching a revolt against the Ottoman Empire. The pledge excluded "portions of Syria" lying to the west of "the districts of Damascus, Homs, Hama and Aleppo". In the decades after the war, the extent of this coastal exclusion was hotly disputed since Palestine lay to the southwest of Damascus and was not explicitly mentioned.
Black powder is thought to have been accidentally discovered by Chinese alchemists using saltpeter and sulfur as materials in their experiments to make gold or prepare an elixir of life. The Zhenyuan Miaodao Yaolue, a Taoist alchemical text from the Late Tang era, warned of a flammable mixture of saltpeter, realgar, sulfur, and honey burning the alchemists preparing it. In China, black powder was first used in fireworks for amusement and religious purposes, as well as in construction works, to blast rocks in order to open roads or waterways; no mention of it being used on the battlefield is made before the 10th century. In weapons, it was first used in incendiary projectiles such as fire arrows and grenades, later joined by the fire lance, an early firearm. The Wujing Zongyao of 1044 described formulas for Chinese black powder and listed a number of Chinese gunpowder weapons, accompanied by illustrations.
ANUBL1; BAG1; BAT3/BAG6; C1orf131; DDI1; DDI2; FAU; HERPUD1; HERPUD2; HOPS; IKBKB; ISG15; LOC391257; MIDN; NEDD8; OASL; PARK2; RAD23A; RAD23B; RPS27A; SACS; 8U SF3A1; SUMO1; SUMO2; SUMO3; SUMO4; TMUB1; TMUB2; UBA52; UBB; UBC; UBD; UBFD1; UBL4A; UBL4B; UBL7; UBLCP1; UBQLN1; UBQLN2; UBQLN3; UBQLN4; UBQLNL; UBTD1; UBTD2; UHRF1; UHRF2;
Sources: en.wikipedia.org
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.
Retention time supports consistency but does not establish structure by itself. A different compound can elute at a similar time under one set of conditions. Mass spectrometry or comparison with a verified standard is normally required alongside the chromatographic result.
The lactam bridge constrains the peptide backbone and limits attack by some exopeptidases. It does not protect against hydrolysis of amide bonds inside the ring or against oxidative modification of susceptible residues. Stability therefore still depends heavily on storage conditions.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.